■COVID-19后病症(PCC)的特征是使人衰弱的持续症状,包括神经异常的症状,如注意力不集中,记忆受损,疼痛,和睡眠障碍。潜在的机制仍然难以捉摸。本研究旨在探讨脑损伤生物标志物,神经认知测试表现,以及PCC年轻人的自我报告的神经和神经心理症状。
■共有404名12-25岁的非住院青少年和年轻人检测出SARS-CoV-2阳性,以及105名匹配的SARS-CoV-2阴性个体,前瞻性纳入并随访6个月(临床试验编号:NCT04686734)。所有参与者都接受了包括临床检查在内的全面评估,问卷,神经认知测试和血液采样。免疫测定血清样品的脑损伤生物标志物神经丝轻链(Nfl)和神经胶质原纤维酸性蛋白(GFAp)。6个月时,血清Nfl/GFAp的横断面分析,神经认知测试结果和症状评分是基于对PCC标准的坚持以及初始SARS-CoV-2测试结果进行的.此外,NFL/GFAp之间的关联,神经认知测试结果,并对症状评分进行了调查。
■在6个月的最终分析中包括了381例SARS-CoV-2阳性和85例SARS-CoV-2阴性,其中48%和47%,分别,遵守PCC标准。Nfl和GFAp的血清水平在组间几乎相等,并且与健康群体中的参考值没有差异。此外,不同组的神经认知测试结果没有差异,而符合PCC标准的患者的症状评分明显较高(与初始SARS-CoV-2状态无关)。Nfl/GFAp之间没有显著关联,神经认知测试结果,并发现了症状评分。
■轻度COVID-19后6个月,正常的脑损伤生物标志物和神经认知能力表明,与PCC相关的持续症状并不与持续的中枢神经系统损伤或认知功能的永久性破坏同时发生。这一发现与神经炎症作为持续症状的可能解释的概念相矛盾。
UNASSIGNED: The post-COVID-19 condition (PCC) is characterized by debilitating persistent symptoms, including symptoms suggesting neurological aberrations such as concentration difficulties, impaired memory, pain, and sleep disturbances. The underlying mechanisms remain elusive. This study aimed to investigate brain injury biomarkers, neurocognitive test performance, and self-reported neurological and neuropsychological symptoms in young people with PCC.
UNASSIGNED: A total of 404 non-hospitalized adolescents and young adults aged 12-25 years who tested positive for SARS-CoV-2, along with 105 matched SARS-CoV-2 negative individuals, were prospectively enrolled and followed-up for 6 months (Clinical Trials ID: NCT04686734). All participants underwent comprehensive assessment encompassing clinical examinations, questionnaires, neurocognitive testing and blood sampling. Serum samples were immunoassayed for the brain injury biomarkers
neurofilament light chain (Nfl) and glial fibrillary acidic protein (GFAp). At 6 months, cross-sectional analyses of serum Nfl/GFAp, neurocognitive test results and symptom scores were performed across groups based on adherence to PCC criteria as well as initial SARS-CoV-2 test results. Also, associations between Nfl/GFAp, neurocognitive test results, and symptom scores were explored.
UNASSIGNED: A total of 381 SARS-CoV-2 positive and 85 SARS-CoV-2 negative were included in the final analysis at 6 months, of whom 48% and 47%, respectively, adhered to the PCC criteria. Serum levels of Nfl and GFAp were almost equal across groups and did not differ from reference values in healthy populations. Also, neurocognitive test results were not different across groups, whereas symptom scores were significantly higher in patients fulfilling PCC criteria (independent of initial SARS-CoV-2 status). No significant associations between Nfl/GFAp, neurocognitive test results, and symptom scores were found.
UNASSIGNED: Normal brain injury biomarkers and neurocognitive performance 6 months after mild COVID-19 implies that the persistent symptoms associated with PCC are not concurrent with ongoing central nervous system damage or permanent disruption of cognitive functions. This finding contradicts the notion of neuroinflammation as a likely explanation for the persistent symptoms.